BCL2 and lymphoma: Using the Pfeiffer DLBCL cell line, Zhao et al. demonstrated that NLRP3 inflammasome activation, induced by ATP and LPS treatment, induced lymphoma cell proliferation and inhibited apoptosis through an upregulation in C-MYC and BCL-2 and downregulation in TP53 and BAX.